NXTC NextCure, Inc.
$7.00▼ -4.24%
Healthcare
Other
After hours
$7.00▲ +0.00%
Sep 11, 7:40 PM ET
Volume 115.3K
Avg Volume (10D) 83.0K
Key Metrics & Fundamentals
Market Cap
$32.04M
P/E Ratio
–
Div Yield
–%
52W Range
1.55 - 15.74
% vs 50 MA
23.84%
% vs 200 MA
-22.65%
RSI-14
53.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.07
Free Cash Flow
-$9.72M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.67M
COGS
–
Operating Exp
$10.02M
Operating Income
-$10.02M
EBIT
-$10.02M
Pretax Income
-$14.89M
Net Income
-$14.89M
EPS (Diluted)
-2.80
Price & Volume History
Loading chart…
Recent News
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
PR Newswire · Aug 10, 2026 11:00 AM
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 6, 2026 8:01 PM
Top Premarket Decliners
MT Newswires · Jul 15, 2026 11:33 AM
Sector Update: Healthcare Stocks Fall Late Afternoon
MT Newswires · Jul 14, 2026 7:46 PM
Top Midday Gainers
MT Newswires · Jul 14, 2026 5:43 PM
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
MT Newswires · Jul 14, 2026 5:40 PM
BC-Most Active Stocks
Associated Press · Jul 14, 2026 2:30 PM
Sector Update: Healthcare Stocks Mixed Premarket Tuesday
MT Newswires · Jul 14, 2026 1:15 PM
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
BioPharma Dive · Jul 14, 2026 12:00 PM
Top Premarket Gainers
MT Newswires · Jul 14, 2026 11:09 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NXTC's money flow as a full page
Social Sentiment
No Reddit posts found for NXTC.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.